CAS: 107254-86-4; 5-Nitro-2-((3-Phenylpropyl)Amino)Benzoic Acid

上下游产品

2-氨基-5-硝基苯甲酸 2-Amino-5-Nitro-Benzoic Acid 616-79-5

📜2-氨基-5-硝基苯甲酸置于sodium Cyanoborohydride,Zinc(II) Chloride体系中,用 甲醇 用作溶剂,化学反应 20.5H,反应生成5-硝基-2-(3-苯丙胺)苯甲酸
参考文献:The Synthesis Of Nppb And Npbb By Reductive Amination And The Effects Of These Compounds On K+ Channels Of The Alga Nitella Hookeri
标题:The Synthesis Of Nppb And Npbb By Reductive Amination And The Effects Of These Compounds On K+ Channels Of The Alga Nitella Hookeri
摘要:This Paper Communicates A,New Synthesis Of The Ion Channel Inhibitors Nppb And Npbb Using A Simple Reductive Amination Sequence. The Synthesised Compounds Were Found To Reduce Channel Amplitude Of A K+ Channel Present In Cytoplasmic Droplets Of Nitella Hookeri. (C) 2002 Elsevier Science Ltd. All Rights Reserved.
Doi:10.1016/s0960-894X(02)00920-4

专利信息

专利号:US-2024239805-A1
优先权日:2022-12-16
标 题:Aza-yang cyclization-buchner aromatic ring expansion: collective synthesis of cycloheptatriene-containing azetidine lactones
发明人：SINGH MANVENDRA PAL; BOSKOVIC ZARKO; GASKINS BRYCE
权利人:UNIV KANSAS
摘要:The present disclosure is directed to a compound of Formula I, Formula II, Formula III, Formula IV, or Formula Vor a pharmaceutically acceptable salt and/or solvate thereof.

专利号:US-11859029-B2
优先权日:2018-07-25
标 题 :Methods of synthesis of homopolymers and non-homopolymers comprising repeating units derived from monomers comprising lactam and acryloyl moieties in an aqueous medium
发明人：DEANE OLIVER JOHNATHAN; MUSA OSAMA M; ARMES STEVEN PETER; FERNYHOUGH ALAN; GIBSON REBECCA ROISIN
权利人:ISP INVESTMENTS LLC
摘要:The invention provides a method for preparation of homopolymers and non-homopolymers comprising polymerizing in an aqueous medium a monomer comprising at least one acryloyl moiety and at least one functionalized or unfunctionalized lactam moiety, and optionally at least one hydrophilic or hydrophobic comonomer, in the presence of at least one chain transfer agent and at least one non-radiation initiator. Exemplary diblock polymers prepared by the method have the structure:where subscripts x, y, and z and variables R, R8, R9 and R10 are described herein.

专利号:US-2007219224-A1
优先权日:2004-05-21
标 题 :Compositions and Methods Relating to Pyrimidine Synthesis Inhibitors
发明人：MATALON SADIS; DAVIS IAN C
权利人:UAB RES FOUNDATION THE
摘要:Provided herein are compositions comprising a pyrimidine synthesis inhibitor and a pharmaceutically acceptable carrier Such compositions can be used in methods of increasing Na + dependent fluid clearance by a pulmonary epithelial cell; of treating a pulmonary disease in a subject; of reducing one or more symptoms or physical signs of a respiratory syncytial virus infection in a subject; of identifying a subject at risk for respiratory syncytial virus infection and administering to the subject a composition comprising an effective amount of a pyrimidine synthesis inhibitor; of identifying a subject with a respiratory syncytial virus infection and administering to the subject a composition comprising a pyrimidine synthesis inhibitor in an amount effective to reduce Na + dependent alveolar fluid in the subject; and of screening for a test compound that increases Na + dependent fluid uptake by a pulmonary epithelial cell.

专利号:US-6187756-B1
优先权日:1996-09-05
标 题 :Composition and methods for treatment of neurological disorders and neurodegenerative diseases
发明人：LEE ROBERT K K; WURTMAN RICHARD J
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:It has been discovered that the stimulation of β-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising β-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by β-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E 2 (PG E 2 ), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of β-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E 2 , forskolin, or nicotine ditartrate is inhibited by immunosuppressants or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

专利号:US-6469055-B2
优先权日:1996-09-05
标题 :Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
发明人：LEE ROBERT K K; WURTMAN RICHARD J
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:It has been discovered that the stimulation of β-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising β-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by β-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E 2 (PG E 2 ), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of β-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E 2 , or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

专利号:US-2023279170-A1
优先权日:2022-03-02
标 题:Chiral-substituted poly-n-vinylpyrrolidinones and complexes with bimetallic nanoclusters and uses thereof
发明人：HUA DUY H
权利人:UNIV KANSAS STATE
摘要:Synthesis of chiral polyvinylpyrrolidinone (CSPVP) compounds, complexes of CSPVP with a core species, such as a bimetallic nanocluster catalyst, and selective C—H bond oxidation reactions utilizing such complexes are disclosed. These reaction products can be used as reagents in the synthesis of complex organic molecules, such as bioactive products, and C—H bond oxidation of complex molecules including various drugs and natural products.